# Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria

> **NCT04944602** · PHASE3 · UNKNOWN · sponsor: **CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.** · enrollment: 340 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **BIOLOGICAL:** SYN008
- **BIOLOGICAL:** Omalizumab for injection

## Key facts

- **NCT ID:** NCT04944602
- **Lead sponsor:** CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07
- **Primary completion:** 2023-03
- **Final completion:** 2023-06
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04944602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04944602, "Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04944602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*